Reporter brief
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract provides no information on which clinical aging measures were assessed or whether rapamycin had any effect on them
- No data are reported on safety outcomes, adverse events, or tolerability
- The sample size, participant characteristics, and follow-up duration are not disclosed, limiting assessment of generalizability or study quality
Study design and sample
Rct; Human.
Healthy older adult population
- Design
- Rct
- Sample
- —
- Journal
- AgelessRx
- Published
- Jan 24, 2024
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.